---
title: "Jeito Capital II's €1B European Biopharma Fund: LPs Back EU Healthcare at Scale"
description: "Jeito Capital's €1B Fund II cements the case that Europe can fund late-stage biopharma domestically, without exporting all growth-stage capital to the U.S."
date: 2026-04-08T00:00:00.000Z
tags: ["2026-vc-news", "venture-capital", "fund-news", "biopharma", "europe-vc", "paris"]
source: https://venturecapitaltracker.com/2026-jeito-capital-ii-1b-european-biopharma
---

# Jeito Capital II's €1B European Biopharma Fund: LPs Back EU Healthcare at Scale

> Jeito Capital's €1B Fund II cements the case that Europe can fund late-stage biopharma domestically, without exporting all growth-stage capital to the U.S.

Paris-based **Jeito Capital** announced **Jeito II, a €1B (~$1.2B) fund** on April 8, 2026, for mid- to late-stage European biopharma companies.

### The problem this fund is attacking
European biopharma has high-quality science but often raises **U.S. growth capital**, moving HQs and tax bases across the Atlantic. Fund vehicles of this size allow quality European clinical-stage assets to scale without forced relocation.

### Why this is a live problem now
- AI-driven drug discovery has compressed pre-clinical timelines, increasing the number of candidates seeking growth capital.
- European universities and spin-outs remain strong sources of differentiated biology.
- Government-backed capital (Bpifrance and others) continues to anchor European biopharma.

### Competitive map
- **Sofinnova Partners**, **Forbion**, **Medicxi**, **Kurma Partners**.
- U.S. firms with EU practices: **Arch Venture Partners**, **OrbiMed**, **RA Capital**.
- Corporate venture arms of pharma giants.

### Market signal (the number to remember)
- **€1B** dedicated to **mid-to-late stage** European biopharma — in one fund — is unusual and consequential.

### Practical takeaway (operator + investor)
1. **Biotech operators**: European late-stage capital is a viable alternative to relocating for a Nasdaq path.
2. **Investors**: EU biopharma funds are competing for a finite set of clinical programs; fund pacing and syndication matter.

### Sources
1. Yutori Scouts fund tracker: https://scouts.yutori.com/8b847103-9d57-41bd-b907-94108a38ecfe

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.